Peptide Therapy: What It Is, Who It's For, How It Works

Peptide therapy is clinician-supervised use of peptide-class compounds — most commonly GLP-1 weight-loss agonists, GH-axis peptides, and healing peptides — for specified indications. The category ranges from FDA-approved prescription drugs (Semaglutide, Tirzepatide, HCG, HGH) to research-use compounds prescribed by specialty clinics under varying degrees of regulatory oversight. This article covers what peptide therapy actually entails, the major indications, what to expect from a clinical program, and how to evaluate a provider.

This article is informational, not medical advice. The peptide therapy landscape is evolving rapidly; the regulatory and clinical-supply situation in the US has shifted multiple times since 2023.

What peptide therapy actually is

In its most-conservative form, peptide therapy is identical to standard endocrinology: a clinician prescribes an FDA-approved peptide drug (Semaglutide, Tirzepatide, HGH, Tesamorelin, PT-141, HCG, Teriparatide, Abaloparatide) for an FDA-approved indication, with standard monitoring.

In its broader form, "peptide therapy" describes clinics that prescribe a wider range of peptides — including research-use compounds like BPC-157, TB-500, Ipamorelin, CJC-1295, Thymosin Alpha-1, and others — for off-label or research-style indications. These are typically compounded prescriptions through specialty pharmacies, with the regulatory environment tightening since 2023.

The major indications

Weight loss

The largest current peptide-therapy category by patient volume. Semaglutide and Tirzepatide are the workhorses; Liraglutide is the older daily-dose option. Trial-stage compounds (Retatrutide, Cagrilintide, Survodutide, Mazdutide, Orforglipron) are visible in the pipeline.

Typical program shape:

• Initial consultation (medical history, current medications, baseline labs).
• Titration schedule 4–16 weeks to maintenance dose.
• Monthly or quarterly follow-up.
• Body-composition and metabolic-panel monitoring.

For the full evidence summary, see peptides for weight loss.

Hormonal optimization

GH-axis peptides (Sermorelin, Tesamorelin, Ipamorelin/CJC-1295 combinations) for body composition, sleep, and recovery in middle-aged and older adults. Most controversial therapeutically — the line between "diagnosed GH deficiency" (FDA-approved indication) and "GH optimization for anti-aging" (not approved, illegal to prescribe for that indication) is regularly blurred by clinics.

Conservative practice: only treat documented adult GH deficiency (insulin tolerance test or arginine-stimulation test confirms low GH response).

Recovery and healing

BPC-157, TB-500, Thymosin Beta-4, GHK-Cu prescribed for soft-tissue injury, surgical recovery, or chronic inflammatory issues. These are research-use peptides; the regulatory basis for compounded-pharmacy prescription tightened significantly in 2023–2024 when FDA pulled BPC-157 from the 503A list.

Sexual health and reproductive hormones

PT-141 (Bremelanotide) FDA-approved for premenopausal HSDD. Kisspeptin, HCG, Gonadorelin, HMG used for fertility and reproductive-axis support.

Cognitive and mood

Semax, Selank, Cerebrolysin prescribed in some specialty practices (more common outside the US). Evidence base is decades of Russian clinical data plus newer Western trials.

Longevity / age-related decline

Epitalon, NAD+ infusions, SS-31 in some clinics. The most speculative category; evidence is largely animal and small-scale human data.

What to expect from a peptide therapy program

A reasonable, conservative program will include:

1. Initial intake — full medical history, current medications, prior peptide or hormone-replacement experience, defined goals.
2. Baseline labs — CBC, CMP, lipid panel, HbA1c, thyroid, sex hormones if relevant, vitamin D, IGF-1 (if running GH-axis peptides). Body-composition scan (DEXA) for body-comp indications.
3. A specific protocol — peptide(s), dose, frequency, route, expected duration, monitoring schedule.
4. Written informed-consent with explicit acknowledgment that the peptide is FDA-approved (and for what indication) or research-use (and the regulatory implications).
5. Pharmacy fulfillment — for FDA-approved peptides, standard retail pharmacy. For research-use compounds, a 503A-compliant compounding pharmacy (note: the list of compoundable peptides has narrowed substantially since 2023).
6. Follow-up — minimum monthly during titration, then quarterly at maintenance.
7. Stop criteria — defined upfront. Side-effect thresholds, lab trends, lack of response.

If a clinic skips any of these — especially baseline labs and written stop criteria — that's a meaningful quality flag.

What it costs

US pricing varies widely.

Category	Typical monthly range
Brand-name GLP-1 (Wegovy, Zepbound, Mounjaro)	$1,000–$1,400
Brand-name GLP-1 with insurance coverage	$25–$300 (highly plan-dependent)
Compounded GLP-1 (where still legal)	$250–$500
GH-axis peptide therapy program	$300–$1,500
BPC-157 / TB-500 / healing peptide course	$200–$800 (compounded; availability tightening)
Initial consult + labs	$200–$800 one-time

See peptide therapy cost for the full breakdown.

How to evaluate a clinic

Look for:

• Board-certified clinicians (MD, DO, NP, PA with relevant scope).
• State-licensed practice in your state.
• A 503A-compliant compounding pharmacy for any research-use compounds.
• Baseline labs included in the protocol (not "optional add-on").
• Defined monitoring schedule in writing.
• Realistic claims. "GLP-1 produces 15–20% weight loss at 18 months" is realistic; "lose 50 lbs in 8 weeks safely" is not.
• Disclosure of conflicts — is the prescribing clinician also dispensing the product?

Red flags:

• No baseline labs. Especially for any GH-axis or hormonal protocol.
• Compounded GLP-1 marketed as identical to brand-name (it is not; quality and bioequivalence vary).
• Telehealth-only with no in-state license. Common scam pattern.
• "Reset" programs with vague mechanisms.
• No written stop criteria.

What the regulatory environment looks like (mid-2026)

• FDA-approved peptides: Standard prescription medications. Available through standard pharmacies. Clinician supervises and prescribes.
• Research-use peptides: Sold legally only labeled "for research purposes only." Not legal to sell for human consumption.
• Compounded peptides (503A pharmacies): A narrowed list compared to 2023. BPC-157, GHK-Cu, KPV, IGF-1 LR3, Selank, Semax, and others were removed from the compoundable list at various points in 2023–2024 following FDA review.
• Telehealth landscape: Significant consolidation in the GLP-1 prescriber space. Many clinics that operated 2020–2023 have shut down or pivoted as FDA tightened compounding rules.

The practical implication: a clinic offering a wide menu of research-use peptides via compounded prescription is operating in a much narrower regulatory space than they did three years ago. Verify the compounding pharmacy is legally able to dispense each specific compound at the time of prescription.

Self-administration vs clinician-supervised

A spectrum:

1. FDA-approved peptide, clinician prescribed, retail pharmacy — standard medicine. The lowest-risk path.
2. Research-use peptide, clinician prescribed, 503A pharmacy — middle ground. Quality-controlled compounding. Some clinical supervision.
3. Research-use peptide, self-administered, sourced from a research-chemical vendor — highest product-quality risk. No clinical oversight. The user is fully responsible for dosing, monitoring, and side-effect management.

Most of what's discussed on this site as "the peptide library" sits in category 2 or 3. The safety frame in are peptides safe? covers the trade-offs.

Where to go from here

• See the per-indication evidence: weight loss, muscle growth, healing.
• See peptide therapy cost for pricing breakdowns.
• Get the safety frame: are peptides safe?, peptide side effects.
• Get the operational guides: how to reconstitute, how to inject, calculator.

PeptidesDB does not run a clinic, prescribe, or sell peptides. Editorial-policy and AI-disclosure: about.